Results 61 to 70 of about 85,335 (283)

AMETHYST: A Retrospective Cohort Study of Treatment Patterns and Outcomes in Patients With Glucocorticoid‐Refractory Macrophage Activation Syndrome Complicating Still's Disease

open access: yesArthritis &Rheumatology, EarlyView.
Objective Information is limited on the natural history and current treatment patterns in macrophage activation syndrome (MAS), a life‐threatening hyperinflammatory syndrome complicating Still's disease (systemic juvenile idiopathic arthritis [sJIA] and adult‐onset Still's disease [AOSD]).
Alexei Grom   +21 more
wiley   +1 more source

Human Monocytic Models Reveal Genotype‐Dependent Inflammatory Programs in VEXAS Syndrome

open access: yesArthritis &Rheumatology, EarlyView.
Objective VEXAS syndrome is a severe X‐linked autoinflammatory disorder caused by somatic mutations in ubiquitin‐like modifier activating enzyme 1 (UBA1), with clinical outcomes that vary by UBA1 genotype. We aimed to elucidate genotype‐specific inflammatory programs and identify potential therapeutic targets.
Kana Higashitani   +10 more
wiley   +1 more source

Tacrolimus induced reversible encephalopathy [PDF]

open access: yes, 2013
Tacrolimus is a novel immunosuppressant used to prevent graft rejection after allogenic organ transplantation. Serious neurological complications of tacrolimus are rare.
Surya, Nirmal, Visana, Devshi
core  

Drug-drug interactions of tacrolimus [PDF]

open access: yes, 2015
Introduction: Tacrolimus, potent immunosupressive drug, has large inter- and intraindividual pharmacokinetic variability. The aim: The aim of this current topic is to describe the importance of tacrolimus drug-drug interactions.
Kovačević Aleksandra M.   +4 more
core   +2 more sources

Novel Insights for Improvement of Tacrolimus Therapy [PDF]

open access: yes, 2020
Individualization of tacrolimus treatment to prevent rejection in kidney transplantation is pivotal. It has been shown that: • Tacrolimus can also be administered by a suppository, contrary to application under the tongue.
Stifft, Frank
core   +1 more source

Oral vancomycin solution is superior to capsule in inducing clinical biomarker and endoscopic remission in children with atypical ulcerative colitis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Atypical colitis (presenting reverse gradient colitis, backwash ileitis or rectal sparing) is associated with primary sclerosing cholangitis–ulcerative colitis (PSC). Oral vancomycin has been used to manage paediatric atypical colitis with/without confirmed PSC. Different preparations had shown different efficacy.
Laura Räisänen   +4 more
wiley   +1 more source

Safety and Efficacy of Infusional Perioperative Tacrolimus Therapy in Crohn’s Disease Patients Undergoing Intestinal Resection

open access: yesInflammatory Intestinal Diseases
Introduction: Perioperative optimization of Crohn’s disease (CD) patients is mandatory in order to ensure favorable outcomes and limit perioperative morbidity such as anastomosis-related complications.
Maximilian Beck   +7 more
doaj   +1 more source

Current evidence and insights on single vs. double dose of basiliximab in adult solid organ transplant recipients: A systematic review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this systematic review was to assess all available clinical data regarding the use of a single dose of basiliximab in solid organ transplantation compared to the standard double dosage, with particular interest in efficacy, safety and cost‐savings.
Alessio Provenzani   +4 more
wiley   +1 more source

Tacrolimus Exposure Before and After a Switch From Twice-Daily Immediate-Release to Once-Daily Prolonged Release Tacrolimus: The ENVARSWITCH Study

open access: yes, 2023
International audienceLCP-tacrolimus displays enhanced oral bioavailability compared to immediate-release (IR-) tacrolimus. The ENVARSWITCH study aimed to compare tacrolimus AUC in stable kidney (KTR) and liver transplant recipients (LTR) on IR ...
Isabelle Etienne   +43 more
core   +1 more source

Home - About - Disclaimer - Privacy